108 related articles for article (PubMed ID: 10858603)
1. Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins.
Masquelier M; Tirzitis G; Peterson CO; Pålsson M; Amolins A; Plotniece M; Plotniece A; Makarova N; Vitols SG
Eur J Med Chem; 2000 Apr; 35(4):429-38. PubMed ID: 10858603
[TBL] [Abstract][Full Text] [Related]
2. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.
Dorlhiac-Llacer PE; Marquezini MV; Toffoletto O; Carneiro RC; Maranhão RC; Chamone DA
Braz J Med Biol Res; 2001 Oct; 34(10):1257-63. PubMed ID: 11593299
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.
Versluis AJ; Rump ET; Rensen PC; Van Berkel TJ; Bijsterbosch MK
Pharm Res; 1998 Apr; 15(4):531-7. PubMed ID: 9587947
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.
Versluis AJ; Rensen PC; Rump ET; Van Berkel TJ; Bijsterbosch MK
Br J Cancer; 1998 Dec; 78(12):1607-14. PubMed ID: 9862571
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Masquelier M; Vitols S; Peterson C
Cancer Res; 1986 Aug; 46(8):3842-7. PubMed ID: 3731059
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells.
Masquelier M; Lundberg B; Peterson C; Vitols S
Leuk Res; 2006 Feb; 30(2):136-44. PubMed ID: 16085310
[TBL] [Abstract][Full Text] [Related]
8. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
Masquelier M; Vitols S; Pålsson M; Mårs U; Larsson BS; Peterson CO
J Drug Target; 2000; 8(3):155-64. PubMed ID: 10938525
[TBL] [Abstract][Full Text] [Related]
9. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells.
Kader A; Pater A
J Control Release; 2002 Apr; 80(1-3):29-44. PubMed ID: 11943385
[TBL] [Abstract][Full Text] [Related]
10. Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway.
Dubowchik GM; Firestone RA
Bioconjug Chem; 1995; 6(4):427-39. PubMed ID: 7578363
[TBL] [Abstract][Full Text] [Related]
11. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
Samadi-Baboli M; Favre G; Canal P; Soula G
Br J Cancer; 1993 Aug; 68(2):319-26. PubMed ID: 8347487
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
Babudri N; Pani B; Tamaro M; Monti-Bragadin C; Zunino F
Br J Cancer; 1984 Jul; 50(1):91-6. PubMed ID: 6378238
[TBL] [Abstract][Full Text] [Related]
13. Delivery of lipophilic drugs using lipoproteins.
Shaw JM; Shaw KV; Yanovich S; Iwanik M; Futch WS; Rosowsky A; Schook LB
Ann N Y Acad Sci; 1987; 507():252-71. PubMed ID: 3442366
[No Abstract] [Full Text] [Related]
14. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors.
Teixeira RS; Valduga CJ; Benvenutti LA; Schreier S; Maranhão RC
J Pharm Pharmacol; 2008 Oct; 60(10):1287-95. PubMed ID: 18812021
[TBL] [Abstract][Full Text] [Related]
15. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives].
Favre G
C R Seances Soc Biol Fil; 1992; 186(1-2):73-87. PubMed ID: 1450992
[TBL] [Abstract][Full Text] [Related]
16. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
[TBL] [Abstract][Full Text] [Related]
17. [Derivatives of daunorubicin containing an inosine fragment].
Olsuf'eva EN; Todorova NP; Iartseva IV; Rozynov BV; Shepelevtseva NG; Preobrazhenskaia MN
Bioorg Khim; 1989 Nov; 15(11):1569-72. PubMed ID: 2624594
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection.
Pérez-Ruiz T; Martínez-Lozano C; Sanz A; Bravo E
Electrophoresis; 2001 Jan; 22(1):134-8. PubMed ID: 11197162
[TBL] [Abstract][Full Text] [Related]
19. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
Povarov LS; Leont'eva OV; Bernaki PD; Olsuf'eva EN; Salimova EI; Pera P; Preobrazhenskaia MN
Bioorg Khim; 1995 Dec; 21(12):925-32. PubMed ID: 8602889
[TBL] [Abstract][Full Text] [Related]
20. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
Manea M; Leurs U; Orbán E; Baranyai Z; Öhlschläger P; Marquardt A; Schulcz Á; Tejeda M; Kapuvári B; Tóvári J; Mezo G
Bioconjug Chem; 2011 Jul; 22(7):1320-9. PubMed ID: 21668011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
